Effect of renal impairment on the pharmacokinetics of antimony in hamsters
Authors:
- I.Y. ZaghloulIZI.Y. Zaghloul
- M. Al-JasserMAM. Al-Jasser
- 1 December 2004
- journal article
- Published by Taylor & Francis in Pathogens and Global Health
- Vol. 98 (8) , 793-800
Abstract
Renal failure was experimentally induced in 36 hamsters by intraperitoneal injection with uranyl nitrate (5 mg/kg). Twenty-four h later [during acute renal failure (ARF), as indicated by the serum concentrations of creatinine and urea nitrogen] or 72 h later [during chronic renal failure (CRF)] these hamsters plus 18, uninjected, control hamsters were each given a single, intramuscular dose of sodium stibogluconate (120 mg pentavalent antimony/kg). The pharmacokinetic parameters for the antimonial drug were calculated using a non-compartmental model. Urine was collected for 72 h after similar treatment with the antimonial drug, from another 30 hamsters (10 controls, 10 with ARF, and 10 with CRF), so that the fraction of the antimony administered that was subsequently excreted in the urine could be estimated. Compared with the controls, both the hamsters with ARF and those with CRF had significantly higher maximum concentrations of antimony (C(max)), significantly larger 'areas under the curve' for the plots of blood concentration v. time, and significantly longer plasma half-lives (P < 0.001 for each). The mean (S.D.) values of C(max), for example, were more than three-fold higher in the hamsters with ARF [467.5 (59.04) microg/ml] or CRF [461.1 (68.9) microg/ml] than in the controls [154.01 (17.3) microg/ml]. The systemic clearance of antimony was also significantly lower in the hamsters with CRF than in the control animals [0.051 (0.002) v. 0.296 (0.047) litres/h/kg; P < 0.01]. In addition, the fraction of the antimony administered that was excreted in urine was significantly lower in the animals with ARF (0.25) or CRF (0.08) than in the controls (0.37), indicating significant dysfunction of the kidneys in the hamsters injected with uranyl nitrate. It seems clear that, if severe toxicity is to be avoided, patients with renal dysfunction requiring treatment (for leishmaniasis) with sodium stibogluconate should be given lower doses than similar cases with normal kidney function.Keywords
This publication has 13 references indexed in Scilit:
- Fluconazole for the Treatment of Cutaneous Leishmaniasis Caused byLeishmania majorNew England Journal of Medicine, 2002
- Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trialCommentary: cost and resistance remain issuesBMJ, 2001
- Management of cutaneous leishmaniasisCurrent Opinion in Infectious Diseases, 2001
- Antimony Excretion in a Patient with Renal Impairment During Meglumine Antimoniate TherapyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000
- High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.The American Journal of Tropical Medicine and Hygiene, 1999
- Successful Treatment of Colombian Cutaneous Leishmaniasis with Four Injections of PentamidineThe American Journal of Tropical Medicine and Hygiene, 1994
- The treatment of kala-azar in the Sudan with sodium stibogluconate: a randomized trial of three dosage regimensTransactions of the Royal Society of Tropical Medicine and Hygiene, 1993
- Pharmacokinetics of Pentavalent Antimony (Pentostam) in HamstersThe American Journal of Tropical Medicine and Hygiene, 1988
- RENAL TUBULAR DYSFUNCTION IN PATIENTS WITH MUCOCUTANEOUS LEISHMANIASIS TREATED WITH PENTAVALENT ANTIMONIALSThe Lancet, 1983
- RENAL CLEARANCE OF PENTAVALENT ANTIMONY (SODIUM STIBOGLUCONATE)The Lancet, 1980